Back to Search
Start Over
Targeting tumor cells with antibodies enhances anti-tumor immunity.
- Source :
- Biophysics Reports; Oct2018, Vol. 4 Issue 5, p243-253, 11p
- Publication Year :
- 2018
-
Abstract
- Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown that tumor-targeting mAb (TTmAb) eradicates tumor cells via activation of cytotoxic T cells (CTLs). In this review, we specifically focus on how TTmAbs induce adaptive anti-tumor immunity and its potential in combination therapy with immune cytokines, checkpoint blockade, radiation, and enzyme-targeted small molecule drugs. Exploring the mechanisms of these preclinical studies and retrospective clinical data will significantly benefit the development of highly efficient and specific TTmAb-oriented anti-tumor remedies. [ABSTRACT FROM AUTHOR]
- Subjects :
- CANCER cells
IMMUNOTHERAPY
ANTINEOPLASTIC agents
IMMUNOGLOBULINS
IMMUNE response
Subjects
Details
- Language :
- English
- ISSN :
- 23643439
- Volume :
- 4
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Biophysics Reports
- Publication Type :
- Academic Journal
- Accession number :
- 133032576
- Full Text :
- https://doi.org/10.1007/s41048-018-0070-2